leadf
logo-loader
viewTRACON Pharmaceuticals
(
NASDAQ:TCON
)

TRACON Pharmaceuticals appoints pharma executive Dr Lisa Johnson-Pratt to its board of directors

The company said Johnson-Pratt will be invaluable to the group as it executes on its plan to complete clinical development and potentially commercialize envafolimab in the US in 2023

TRACON Pharmaceuticals -
Dr Johnson-Pratt is currently serves as the senior vice president, New Product Planning at Ionis Pharmaceuticals

TRACON Pharmaceuticals Inc (NASDAQ:TCON) said it has appointed Dr Lisa Johnson-Pratt to the company’s board of directors.

TRACON noted that Dr Johnson-Pratt brings more than two decades of broad business and commercialization leadership experience to the company and she currently serves as the senior vice president, New Product Planning at Ionis Pharmaceuticals, Inc.

“We are very pleased to welcome Lisa to TRACON’s Board of Directors. She is a physician who has focused the majority of her career on the commercialization of innovative products, including Gardasi and Singulairat Merck, prior to her appointment as Head of the Global Commercial Operations at GlaxoSmithKline PLC (GSK),” TRACON CEO Dr Charles Theuer said in a statement.

READ: TRACON Pharmaceuticals ends FY2020 with $36.1M in cash and equivalents

He added: “Her strong track record of successful strategic, operational and financial management, combined with her vast commercial experience will be invaluable to TRACON as we execute on our plan to complete clinical development and potentially commercialize envafolimab in the United States in 2023.”

Dr Johnson-Pratt commented: “TRACON has a first-class management team, an efficient platform to conduct global clinical trials, and a promising drug candidate with near-term commercial potential in envafolimab.”

“I am thrilled to support TRACON’s mission to commercialize envafolimab and address significant unmet needs in patients with cancer,” she added.

Dr Johnson-Pratt joined Ionis following its acquisition of Akcea Therapeutics, where she was an Executive Council member and led an integrated medical team responsible for the commercialization strategy of two novel late-stage antisense assets.

Before that, she was head of Global Pharma Commercial Operations at GSK. During her time there, she also served as head of Early Pipeline Commercial Strategy supporting assets in early-stage development across multiple therapeutic areas, including oncology.

TRACON has positioned itself as a collaboration partner that leads the regulatory filings, clinical trials, as well as US commercialization of best-in-class drug candidates, as an alternative to expensive contract research organization (CRO) based development.

Contact Sean at sean@proactiveinvestors.com

Quick facts: TRACON Pharmaceuticals

Follow
NASDAQ:TCON

Price: 4.31 USD

Market Cap: $83.36 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

TRACON's ENVASARC trial to continue after 2nd Independent Data Monitoring...

TRACON Pharmaceuticals (NASDAQ:TCON) Inc (NASDAQ:TCON) CEO Charles Theuer spoke to Proactive about the latest advancements on its ENVASARC trial to treat cancer with its therapy called envafolimab. Theuer says that the Independent Data Monitoring Committee has recommended that the trial...

on 08/10/2021

2 min read